FDA Vertex Pharmaceuticals - Search News

Vertex Pharmaceuticals Shares Gain

MarketWatch · 2h

Vertex Pharmaceuticals stock is soaring. The FDA just approved its potentially game-changing pain treatment.

Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved the company’s non-opioid pain treatment.

CNBC on MSN · 12h

FDA approves Vertex’s non-opioid painkiller, first new kind of pain medicine in decades

The Vertex drug is a milestone after a long history of unsuccessful efforts to develop painkillers without the addictive potential of opioids.

The Wall Street Journal on MSN · 11h

Vertex Pharmaceuticals Shares Gain After FDA Approves Non-Opioid Pain Drug

Shares of Vertex Pharmaceuticals rose after Journavx, the company’s oral non-opioid pain medication, received Food and Drug Administration approval.

56m

Vertex Pharmaceuticals price target raised to $435 from $418 at Barclays

Barclays analyst Gena Wang raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $435 from $418 and keeps an Equal Weight rating ...

Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...

2h

FDA green lights new painkiller

The new drug type targets pathways in the peripheral nervous system before pain signals reach the brain, potentially lowering ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results